Clinical Trial Update: RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 [Phase 2]

View source ↗

Summary

Phase 2 trial updating the combination of RC48-ADC with Envolizumab in locally advanced or metastatic biliary tract cancer with positive HER-2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Envolizumab (envolizumab)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Biliary Tract Cancer | Phase 2 | Status: UNKNOWN